2013
DOI: 10.1016/j.toxlet.2013.09.014
|View full text |Cite
|
Sign up to set email alerts
|

Dexamethasone accelerates degradation of aryl hydrocarbon receptor (AHR) and suppresses CYP1A1 induction in placental JEG-3 cell line

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
6
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 17 publications
(9 citation statements)
references
References 37 publications
3
6
0
Order By: Relevance
“…In addition, tapinarof-induced upregulation of the mRNA level of CYP1A1, a typical AHR-responsive gene, was found to be partially inhibited by dexamethasone (Supplementary Figure S5A). These findings suggest that glucocorticoid treatment interferes with AHR activation induced by tapinarof treatment, which is consistent with reports describing that dexamethasone suppresses AHR agonist-mediated CYP1A1 upregulation in human ovarian granulosa [41] and choriocarcinoma cell lines [42]. We also found that baricitinib or JTE-052 did not interfere with the upregulation of CYP1A1 mRNA expression induced by tapinarof treatment (Supplementary Figure S5E,F), confirming that they did not act directly on AHR activation.…”
Section: Cell Culturesupporting
confidence: 92%
“…In addition, tapinarof-induced upregulation of the mRNA level of CYP1A1, a typical AHR-responsive gene, was found to be partially inhibited by dexamethasone (Supplementary Figure S5A). These findings suggest that glucocorticoid treatment interferes with AHR activation induced by tapinarof treatment, which is consistent with reports describing that dexamethasone suppresses AHR agonist-mediated CYP1A1 upregulation in human ovarian granulosa [41] and choriocarcinoma cell lines [42]. We also found that baricitinib or JTE-052 did not interfere with the upregulation of CYP1A1 mRNA expression induced by tapinarof treatment (Supplementary Figure S5E,F), confirming that they did not act directly on AHR activation.…”
Section: Cell Culturesupporting
confidence: 92%
“…While cotreated with TCDD + Dex, AHR translocation was significantly decreased. In contrast, GR translocation was also significantly reduced by TCDD + Dex, consistent with a previous report that Dex downregulated AHR protein level by AHR degradation in the presence of AHR ligand in JEG-3 cells [28]. Our results suggest that the reduction of AHR nuclear translocation by Dex treatment might be a critical mechanism of inhibition of AHR target gene expression by Dex treatment.…”
Section: Resultssupporting
confidence: 92%
“…In the study by Davarinos and Pollenz [18], treatment of rat smooth muscle cells with MG132 had no effect on AhR protein unless cotreated with TCDD, which prevented AhR degradation. Interestingly, we recently observed a decrease in AhR protein in JEG-3 choriocarcinoma cell line treated with MG132 or bortezomib [45], consistently with our observation in hepatocytes (Figure 3c). Surprisingly, the PXR protein level was affected quite differently by MG132 or bortezomib.…”
Section: Discussionsupporting
confidence: 91%